Black Rock Inc. Cidara Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 715,410 shares of CDTX stock, worth $8.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

715,410

Previous 938,161 23.74%

Holding current value

$8.02 Million

Previous $741,000 11.2%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.64 - $0.92 $142,560 - $204,930	-222,751 Reduced 23.74%	715,410 $658,000
Q4 2023 Feb 13, 2024	SELL	$0.68 - $0.97 $3,433 - $4,897	-5,049 Reduced 0.54%	938,161 $741,000
Q3 2023 Nov 13, 2023	SELL	$0.77 - $1.16 $14,251 - $21,469	-18,508 Reduced 1.92%	943,210 $886,000
Q2 2023 Aug 11, 2023	BUY	$1.01 - $1.42 $222,205 - $312,407	220,005 Added 29.66%	961,718 $1.09 Million
Q1 2023 May 12, 2023	BUY	$0.75 - $1.98 $456,935 - $1.21 Million	609,247 Added 459.93%	741,713 $941,000

Q4 2022 Feb 13, 2023	SELL	$0.48 - $0.76 $30,788 - $48,748	-64,143 Reduced 32.62%	132,466 $100,000
Q3 2022 Nov 14, 2022	SELL	$0.45 - $0.81 $16,460 - $29,628	-36,579 Reduced 15.69%	196,609 $124,000
Q2 2022 Aug 12, 2022	SELL	$0.43 - $0.91 $63,378 - $134,125	-147,391 Reduced 38.73%	233,188 $114,000
Q1 2022 May 12, 2022	BUY	$0.67 - $1.39 $2,795 - $5,799	4,172 Added 1.11%	380,579 $317,000
Q4 2021 Feb 10, 2022	BUY	$1.18 - $2.18 $52,322 - $96,663	44,341 Added 13.35%	376,407 $478,000
Q3 2021 Nov 09, 2021	SELL	$1.48 - $2.35 $56,721 - $90,063	-38,325 Reduced 10.35%	332,066 $743,000
Q2 2021 Aug 11, 2021	BUY	$1.87 - $2.7 $692,631 - $1 Million	370,391 New	370,391 $747,000

Others Institutions Holding CDTX

# of Institutions

Shares Held

22.2M

Call Options Held

2.7K

Put Options Held

100

View Full List

About Cidara Therapeutics, Inc.

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $786M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

More about CDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account